Caladrius Biosciences to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 13, 2020
August 06 2020 - 8:30AM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a clinical-stage biopharmaceutical company dedicated to
the development of cellular therapies designed to reverse, not
simply manage, disease, today announced that it will report
financial results for the three and six months ended June 30, 2020
after the close of the U.S. financial markets on Thursday, August
13, 2020.
Caladrius management will host a conference call
for investors beginning at 4:30 p.m. (ET) on Thursday, August 13,
2020 to discuss the financial results and provide a business
update.
Shareholders and other interested parties may
participate in the conference call by dialing 866-595-8403
(domestic) or 706-758-9979 (international) and referencing
conference ID number 2093833. The conference call will also be
webcast live under the Investors section on the Company's website
at www.caladrius.com.
For those unable to participate in the live
conference call, a replay will be accessible approximately two
hours after its completion through August 20, 2020, by dialing
855-859-2056 (domestic) or 404-537-3406 (international) and
referencing conference ID number 2093833. A webcast audio recording
of the call will also be archived for 90 days under the Investors
section of the Company’s website at www.caladrius.com.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage
biopharmaceutical company dedicated to the development of cellular
therapies designed to reverse, not manage, disease. We are
developing a first- in-class cell therapy product that is based on
the notion that our body contains finely tuned mechanisms for
self-repair. Our technology leverages and enables these mechanisms
in the form of specific cells, using formulations and modes of
delivery unique to each medical indication.
The Company's current product candidates include
CLBS119, a CD34+ cell therapy product candidate for the repair of
lung damage found in patients with severe COVID-19 infection who
experienced respiratory failure, for which the Company plans to
initiate a clinical trial in the coming months, as well as three
developmental treatments for ischemic diseases based on its CD34+
cell therapy platform: CLBS12, recipient of SAKIGAKE designation
and eligible for early conditional approval in Japan for the
treatment of critical limb ischemia ("CLI") based on the results of
an ongoing clinical trial; CLBS16, the subject of a recently
completed positive Phase 2 clinical trial in the U.S. for the
treatment of coronary microvascular dysfunction ("CMD"); and
CLBS14, a Regenerative Medicine Advanced Therapy ("RMAT")
designated therapy for which the Company has finalized with the
U.S. Food and Drug Administration (the "FDA") a protocol for a
Phase 3 confirmatory trial in subjects with no-option refractory
disabling angina ("NORDA"). For more information on the company,
please visit www.caladrius.com.
Contact:
Investors: Caladrius Biosciences, Inc. John
Menditto Vice President, Investor Relations and Corporate
Communications Phone: +1-908-842-0084
Email: jmenditto@caladrius.com
Media:W2O GroupChristiana PascalePhone:
+1-212-257-6722Email: cpascale@w2ogroup.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Apr 2023 to Apr 2024